Request Trial
searching-questions
Ollyy / Shutterstock.com
20 June 2014Asia-PacificWolfgang Bublak and Yingkun Brunner

Utility models: searching questions

China has, historically, been comparatively weak in the fields of science and technology innovation, not least in the life sciences. The inventions and creations of many small and medium-sized enterprises were of a low standard technically, and the majority were of limited importance.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Australia boutique hires experienced life sciences litigator
23 February 2023   New recruit joins from DLA Piper and will head up firm’s litigation team | Previously worked on Pfizer v Samsung Bioepis, Jusand v Rattlejack & Murray Engineering, and Pfizer v Sandoz | Follows prosecutor Chris Vindurampulle who joined in October last year.
Asia-Pacific
Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent
24 May 2022   The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.
Asia-Pacific
Wyeth secures Australian injunction against MSD vaccine
30 November 2020   The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.


Editor's picks

SCOTUS shuts the door on Entresto ‘after-arising technology’ review
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

Editor's picks

Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025
Europe
Biotech cleared to make biosimilar of $6bn treatment after landmark ruling
25 November 2025
Americas
INTA votes in new 2026 president at Florida leadership meeting
20 November 2025

More features

Regeneron v Alvotech: The big impact
Beyond traditional IP: A comprehensive AI strategy for life sciences
Prosecuting bispecific antibody patents: A cookbook for patent chefs
FisherBroyles grows IP practice with experienced patent attorney
EU Pharma Package hits the final stretch—but can negotiators agree?
The clinical trial dilemma: Navigating European practice
Still Unsettling: The uncertain landscape for discretionary denial
WIPR Rankings reveals the go-to firms and attorneys for China patent work